Authors
Latest:
Why wait? The data show administering steroids to DME patients with good vision leads to long-term successA review of the phase 4 PALADIN data show that steroid-eluting implants lead to good vision, safe outcomes, and reduced burden in patients with DME.
Latest:
Saving the world: Pharmaceutical innovation in nine monthsThe COVID-19 vaccine, and the speed at which it was developed, is the medical breakthrough of our lifetimes.
Latest:
Jean-Francois Korobelnik, MD, says surgeons under-utilize a key surgical toolAt the 2025 EURETINA Congress, Prof Korobelnik delivered the Gisbert Richard Lecture, focusing on removal of intra-ocular foreign bodies and mitigating ocular trauma.
Latest:
Q&A: Alan J. Franklin, MD, PhD, on postoperative methotrexate injectionsFranklin shares how methotrexate significantly reduces reoperation rates in diabetic patients with retinal detachments, enhancing postoperative outcomes and vision.
Latest:
Q&A: Jennifer I. Lim, MD, shares insights from the DAVIO-2 studyThe DAVIO-2 study reveals EYP-1901's potential as a 6-month treatment for neovascular AMD, matching aflibercept's vision outcomes with fewer doses.
Latest:
Expert insights: Ashkan Abbey, MD discusses 1-year results of DAVIO-2 trialAshkan Abbey, MD, shares insights from the one-year data for the phase 2 DAVIO2 trial and the impact of tyrosine kinase inhibitors on reducing treatment burden.
Latest:
Harvey Uy, MD, DPBO, FVRSP, says AI brings a fifth dimension to retina careAt the EURETINA meeting, Professor Uy described the ways artificial intelligence can augment an existing imaging workflow.
Latest:
Using virtual reality mobility testing as a standardized clinical end point in inherited retinal disordersThe use of VR mazes hold an intrinsic advantage compared with physical mazes in the ability to control conditions and test various patterns with reliability, participant safety, and repeatability.
Latest:
Microaneurysm turnover predicts diabetic retinopathy progressionMicoaneurysm turnover in the early stages of diabetic retinopathy predicts how much the disease will progress, according to researchers.
Latest:
Electroretinography: Out of the laboratory and into the clinicOCT has many benefits, yet falls short of reliably diagnosing and managing retinopathies and glaucoma. ERG remains the stalwart method for this application and this article highlights how technological advancements have enabled its introduction to the clinic.
Latest:
ASRS 2019 Street Team: W. Lloyd Clark, MDICYMI: Dr. Clark breaks down the results of the PANORAMA Study
Latest:
Diagnosing early-stage AMD with a dark adaptation deviceA dark adaptometer (AdaptDx; MacuLogix Inc) can aid in the diagnosis of early-stage, or subclinical, age-related macular degeneration before visual loss occurs and even before structural changes are observed, and adds to the information obtained from retina cameras and OCT imaging.
Latest:
Applying AI in fundus imagesFDA decision changes scope of healthcare delivery; increases patient access to early detection of DR
Latest:
Nailing intravitreal implant injectionsTreating diabetic macular edema (DME) has evolved from the ETDRS-style focal/grid laser being the standard of care since 1985 to the modern era of pharmacotherapy-with anti-vascular endothelial growth factor (VEGF) injections now taking center stage as primary treatment for most patients.
Latest:
Retina surgeon’s AMD regimen at center of Medicare fraud caseEarlier this month, a jury convicted West Palm Beach retina surgeon Solomon Melgen, MD, on 67 counts of Medicare fraud. This high-profile case hit very close to home, as myself and another retina specialist from my own community were on opposing sides of the case.
Latest:
Novel therapies abound in pipelineThe importance of novel therapies for ocular disease is a given. However, as most novel therapies are financed by the private sector, it is fortunate that investors find ophthalmology a worthwhile investment.
Latest:
Diagnosing and treating MacTel degenerative retinal diseaseIdiopathic macular telangiectasia (MacTel) is bilateral condition characterised by ectatic capillaries of the macula and atrophy of the neurosensory retina. Familiarity with the distinctive intraretinal cavitation on SD-OCT in type 2, the most common type, is key for correct diagnosis.
Latest:
Scleral buckle technique using PPV, laser photocoagulationScleral buckles and vitrectomy are the two main procedures used today to treat retinal detachments, with many surgeons performing a combination of the two.
Latest:
Assessing the impact of FLACS on surgical outcomesFLACS is related to an increase of anterior chamber prostaglandin and cytokines, resulting in intra-operative miosis. This can be prevented by pre-operative non-steroidal anti-inflammatory drug application. As a result of methodological problems, several studies on the association between femtosecond laser-assisted cataract surgery and cystoid macular oedema are inconclusive.
Latest:
Assessing the impact of FLACS on surgical outcomesFLACS is related to an increase of anterior chamber prostaglandin and cytokines, resulting in intra-operative miosis. This can be prevented by pre-operative non-steroidal anti-inflammatory drug application. As a result of methodological problems, several studies on the association between femtosecond laser-assisted cataract surgery and cystoid macular oedema are inconclusive.
Latest:
Outer retinal layer thickness predicts visual acuity in diabetic macular oedemaDiabetes mellitus is a common health problem in developed countries, with diabetic macular oedema (DMO) being a major cause of visual loss. A variety of treatment modalities for DMO are available including laser, steroid and intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents.
Latest:
Diagnosing and treating MacTel degenerative retinal diseaseIdiopathic macular telangiectasia (MacTel) is bilateral condition characterised by ectatic capillaries of the macula and atrophy of the neurosensory retina. Familiarity with the distinctive intraretinal cavitation on SD-OCT in type 2, the most common type, is key for correct diagnosis.
Latest:
Outer retinal layer thickness predicts visual acuity in diabetic macular oedemaDiabetes mellitus is a common health problem in developed countries, with diabetic macular oedema (DMO) being a major cause of visual loss. A variety of treatment modalities for DMO are available including laser, steroid and intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents.
Latest:
Prevent Blindness observes inherited retinal disease genetic testing week May 16-22Prevent Blindness dedicates the third week of May to raising awareness of the benefit of genetic testing, variety of retinal diseases, and available resources.
Latest:
2023: What awaits ophthalmology in the year aheadAs we approach the end of 2022, members of the Ophthalmology Times Europe® Editorial Advisory Board were asked to predict developments in their ophthalmic specialties and interests. A focus is our ageing population, while efficiency and productivity are also on their minds. The board members agree that one of the major challenges in the year to come will be the large number of patients awaiting diagnosis and treatment, which is only going to increase with the rising average life expectancy worldwide.
Latest:
Considering YAG vitreolysis for persistent vitreous floatersStudy evaluates the impact of surgical procedure on visual outcomes in patients
Latest:
SNAPS Eye Shield: Creating the gold standard for postoperative ocular protectionDespite its status as an essential postoperative safety eye product and its utilization by every ocular surgeon with every ocular surgery, eye shield innovation has been neglected to date.
